The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major advancement in schizophrenia treatment in decades. Unlike existing medications that ...
As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...
How Does Cobenfy Work, and How Is It Different From Other Medicines Used to Treat Schizophrenia? An imbalance of brain chemicals called neurotransmitters may contribute to schizophrenia. Current ...
No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...
The general consensus among experts is that TRS is a condition in which an individual’s symptoms haven’t responded to two or more antipsychotic medicines given at a therapeutic dose for at least six ...
On December 11, 1951, in the labs of French pharmaceutical company Rhône-Poulenc, chemist Paul Charpentier concocted a drug that would change the field of psychiatry forever. Charpentier hadn’t ...
Credit: Getty Images A literature review of nonpharmacologic treatments for patients with schizophrenia and comparison recommendations in the 2020 American Psychiatric Association Practice (APA) ...
Panelists discuss how CT-155, a 16-week interactive digital application, met its primary end point in clinical trials by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback